Health Canada approves AstraZeneca's COVID-19 vaccine

26 February 2021 - Canada's regulator estimates vaccine's efficacy at 62.1 per cent. ...

Read more →

Emgality (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache

25 February 2021 - The first and only anti-CGRP treatment with dual indications. ...

Read more →

Medexus announces expanded availability of Gleolan in Canada

25 February 2021 - Medexus Pharmaceuticals announced today that it has initiated the commercial launch of Gleolan in Canada, which had ...

Read more →

Bladder cancer drug shortage resolved with Health Canada approval

24 February 2021 - Verity-BCG bladder cancer treatment available for Canadian patients in the spring. ...

Read more →

Health Canada approves Dupixent (dupilumab) as the first biologic for the treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years

23 February 2021 - Dupixent is the only biologic medicine approved to treat atopic dermatitis for this patient population. ...

Read more →

AstraZeneca vaccine review is in the 'final stages,' Health Canada says

22 February 2021 - Health Canada has received all the necessary scientific data but questions for the company remain. ...

Read more →

Where is AstraZeneca’s vaccine? Health Canada says not yet ready to greenlight

18 February 2021 - Health Canada is not yet ready to make a decision about approving the COVID-19 vaccine from ...

Read more →

Viatris launches Hulio (adalimumab biosimilar) in Canada

18 February 2021 - Viatris announced today that Health Canada has approved Hulio, and product is now available in Canada. ...

Read more →

Ultragenyx announces approval of Dojolvi (UX007/triheptanoin) in Canada for the treatment of long-chain fatty acid oxidation disorders in adults and children

17 February 2021 - First approved treatment for adult and paediatric patients with long-chain fatty acid oxidation disorders in Canada. ...

Read more →

Sandoz Canada completes its fifth biosimilar launch with new biosimilar Hyrimoz (adalimumab)

16 February 2021 - Hyrimoz for use in nine indications covered by the reference medicine in the fields of rheumatology, gastro-enterology ...

Read more →

Health Canada approves Reblozyl (luspatercept), new class of treatment for adult patients living with myelodysplastic syndromes

16 February 2021 - Reblozyl, an erythroid maturation agent, is the first and only of its kind approved for use in ...

Read more →

Pay for plasma collection coming to Alberta by end of the year

14 February 2021 - Repeal of NDP bill last fall clears way for Canadian Plasma Resources to set up shop. ...

Read more →

Health Canada authorises Dayvigo (lemborexant)

4 February 2021 - Now available in Canada for the treatment of insomnia in adults. ...

Read more →

Novavax announces start of rolling review by multiple regulatory authorities for COVID-19 vaccine authorisation

4 February 2021 - Rolling reviews have commenced by FDA, MHRA, EMA and Health Canada. ...

Read more →

Celltrion Healthcare receives Health Canada marketing authorization for world's first subcutaneous formulation of infliximab, Remsima SC, for the treatment of people with rheumatoid arthritis

1 February 2021 - This novel formulation provides an alternative administration option for Canadian physicians and their patients. ...

Read more →